Cellosaurus logo
expasy logo

Cellosaurus BHP 2-7 (CVCL_6283)

[Text version]
Cell line name BHP 2-7
Synonyms BHP2-7; BHP-2
Accession CVCL_6283
Resource Identification Initiative To cite this cell line use: BHP 2-7 (RRID:CVCL_6283)
Comments Problematic cell line: Contaminated. Shown to be a TPC-1 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764).
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00182.
Population: Japanese.
Omics: Mitochondrial genome sequenced.
Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
Sequence variations
  • Gene fusion; HGNC; HGNC:18782; CCDC6 + HGNC; HGNC:9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line).
  • Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
Disease Thyroid gland papillary carcinoma (NCIt: C4035)
Differentiated thyroid carcinoma (ORDO: Orphanet_146)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_6298 (TPC-1)
Children:
CVCL_4W01 (BHP2-7 Pazopanib selected)
Sex of cell Female
Age at sampling Adult
Category Cancer cell line
STR profile Source(s): PubMed=18713817; PubMed=21868764; PubMed=25365311

Markers:
AmelogeninX
CSF1PO8,10 (PubMed=25365311)
11,12 (PubMed=21868764)
D3S135816,17
D5S8188,10
D7S8209,11 (PubMed=25365311)
11 (PubMed=21868764)
D13S31711,12
D16S5399
D18S5113,16
D21S1130,31.2
FGA20,21
TH019 (PubMed=21868764)
11 (PubMed=25365311)
TPOX11
vWA14,18

Run an STR similarity search on this cell line
Web pages https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
Publications

PubMed=9253346; DOI=10.1210/jcem.82.8.4136
Ohta K., Pang X.-P., Berg L., Hershman J.M.
Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor.
J. Clin. Endocrinol. Metab. 82:2633-2638(1997)

PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

PubMed=25365311; DOI=10.1210/jc.2014-2359; PMCID=PMC4318896
Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T., Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S., Liu L.-Z., Tan K.-T., Chang W.J., Yang H.H., Ogawa S., Koeffler H.P.
Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.
J. Clin. Endocrinol. Metab. 100:725-735(2015)

PubMed=29066502; DOI=10.1530/ERC-17-0288
Corver W.E., Demmers J., Oosting J., Sahraeian S., Boot A., Ruano D., van Wezel T., Morreau H.
ROS-induced near-homozygous genomes in thyroid cancer.
Endocr. Relat. Cancer 25:83-97(2018)

PubMed=31443247; DOI=10.3390/cancers11081185; PMCID=PMC6721552
Aydemirli M.D., Corver W.E., Beuk R., Roepman P., Solleveld-Westerink N., van Wezel T., Kapiteijn E.H.W., Morreau H.
Targeted treatment options of recurrent radioactive iodine refractory Hurthle cell cancer.
Cancers (Basel) 11:1185.1-1185.16(2019)

Cross-references
Cell line databases/resources Lonza; 783
Biological sample resources BioSample; SAMN03151970
Encyclopedic resources Wikidata; Q54796499
Polymorphism and mutation databases Cosmic; 1005446
Cosmic; 1094764
Entry history
Entry creation04-Apr-2012
Last entry update19-Dec-2024
Version number28